GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CStone Pharmaceuticals 2616.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

5.41

+1.12%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥314.0m

FY2016FY2025

Net income

−CN¥508.9m

FY2016FY2025

Free cash flow

−CN¥381.7m

FY2016FY2025

Shareholders' equity

CN¥718.6m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥314.0mCN¥407.2mCN¥463.8mCN¥481.4mCN¥283.8mCN¥1.21bn—CN¥12.6mCN¥10.3m—
Research and developmentCN¥362.8mCN¥134.7mCN¥527.8mCN¥614.2mCN¥1.52bnCN¥1.64bnCN¥1.40bnCN¥850.2mCN¥213.4mCN¥247.1m
Operating income−CN¥503.8m−CN¥91.7m−CN¥605.6m−CN¥912.1m−CN¥2.13bn−CN¥1.27bn−CN¥1.74bn−CN¥1.03bn−CN¥242.5m−CN¥262.2m
Net income−CN¥508.9m−CN¥91.2m−CN¥367.2m−CN¥902.7m−CN¥2.24bn−CN¥1.42bn−CN¥2.31bn−CN¥1.75bn−CN¥308.9m−CN¥246.1m
Diluted earnings per share-0.35-0.07-0.29-0.77-1.90-1.21-2.32-1.77-0.31-0.25

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥1.58bnCN¥1.62bnCN¥1.94bnCN¥1.91bnCN¥2.65bnCN¥4.38bnCN¥2.95bnCN¥1.63bnCN¥564.3mCN¥826.1m
Cash and short-term investmentsCN¥1.07bnCN¥783.7mCN¥1.22bnCN¥1.21bnCN¥2.01bnCN¥3.95bnCN¥2.74bnCN¥1.56bnCN¥537.7mCN¥811.9m
Total liabilitiesCN¥863.7mCN¥1.20bnCN¥1.40bnCN¥1.38bnCN¥1.24bnCN¥941.3mCN¥469.1mCN¥1.12bnCN¥113.2mCN¥59.2m
DebtCN¥405.4mCN¥356.0mCN¥363.4mCN¥286.3mCN¥174.2mCN¥83.9mCN¥4.3m———
Shareholders' equityCN¥718.6mCN¥423.8mCN¥532.0mCN¥523.3mCN¥1.41bnCN¥3.44bnCN¥2.48bnCN¥515.3mCN¥426.3mCN¥712.7m
Shares outstanding1,463m1,277m1,274m1,169m1,176m1,174m994m984m984m984m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−CN¥381.7m−CN¥343.2m−CN¥685.8m−CN¥713.3m−CN¥1.73bn−CN¥508.1m−CN¥1.08bn−CN¥791.1m−CN¥240.2m−CN¥213.0m
Capital spending——−CN¥75.8m−CN¥118.6m−CN¥173.7m−CN¥71.4m−CN¥10.4m−CN¥7.9m−CN¥12.5m−CN¥1.1m
Free cash flow−CN¥381.7m−CN¥343.2m−CN¥761.5m−CN¥831.9m−CN¥1.90bn−CN¥579.5m−CN¥1.09bn−CN¥799.0m−CN¥252.7m−CN¥214.1m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023
RevenueCN¥235.6mCN¥256.4mCN¥28.8mCN¥153.0mCN¥89.1mCN¥254.2mCN¥148.0mCN¥202.4m
Operating income−CN¥270.8m−CN¥181.1m−CN¥161.4m−CN¥102.4m−CN¥59.6m−CN¥3.7m−CN¥2.1m−CN¥351.6m
Net income−CN¥289.8m−CN¥194.3m−CN¥157.3m−CN¥106.9m−CN¥62.3mCN¥15.7mCN¥9.1m−CN¥158.0m
Diluted earnings per share-0.19-0.13-0.11-0.08-0.050.010.01-0.12
Cash from operations—−CN¥65.0m−CN¥345.0m−CN¥156.0m—−CN¥187.0m−CN¥108.0m−CN¥248.0m
Total assetsCN¥2.39bnCN¥1.58bnCN¥1.39bnCN¥1.39bnCN¥1.62bnCN¥1.53bnCN¥1.78bnCN¥1.66bn
Cash and short-term investmentsCN¥1.82bnCN¥1.07bnCN¥803.7mCN¥672.9mCN¥838.4mCN¥857.6mCN¥998.8mCN¥1.05bn
DebtCN¥195.2mCN¥405.4mCN¥455.8mCN¥356.0mCN¥108.6mCN¥334.7mCN¥114.5mCN¥363.4m
Shareholders' equityCN¥1.50bnCN¥718.6mCN¥366.9mCN¥363.9mCN¥423.8mCN¥467.7mCN¥544.6mCN¥456.8m

Financial ratios

Data as of 6 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating margin-154.2%-23.4%-76.6%-185.8%-786.9%-117.4%——
Net margin-162.1%-22.4%-79.2%-187.5%-787.8%-117.4%——
Return on equity-70.8%-25.1%-80.4%-200.9%-159.1%-41.3%——
Return on assets-32.2%-6.5%-22.1%-55.1%-84.5%-32.4%——
Free cash flow yield——-7.0%-7.5%-19.4%-6.4%-18.4%-13.6%
Revenue growth-33.8%-12.2%-3.6%97.5%-76.5%——21.8%
Earnings growth379.1%-75.2%-59.3%-53.0%57.4%-47.2%——
Current ratio2.18x1.60x1.56x1.32x2.10x4.91x——
Debt to equity0.56x0.96x0.77x0.59x0.13x0.02x——
Equity ratio45.4%26.1%27.5%27.4%53.1%78.5%——
Interest coverage-32.16x-6.29x-30.07x-105.49x-855.42x-924.00x——
R&D as a share of sales115.6%33.1%113.8%127.6%535.4%135.2%——
Buybacks as a share of market value-14.5%-0.2%-9.0%0.5%-0.1%-18.1%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-13.3%-23.6%—
Operating income-18.0%-16.9%—
Net income-17.4%-18.6%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings-13.2-27.9-6.8-5.2-3.8-7.2-3.8
Price to sales21.56.35.49.729.78.5—

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.